Thromb Haemost 2009; 102(06): 1251-1258
DOI: 10.1160/TH08-06-0406
Platelets and Blood Cells
Schattauer GmbH

Dynamics of platelet mobilisation into lungs in response to 5-hydroxytryptamine (serotonin) in mice

Zhiqian Yu
1   Department of Oral Diagnosis, Graduate School of Dentistry, Tohoku University, Sendai, Japan
2   Department of Oral Molecular Regulation, Graduate School of Dentistry, Tohoku University, Sendai, Japan
,
Mami Ohba
1   Department of Oral Diagnosis, Graduate School of Dentistry, Tohoku University, Sendai, Japan
2   Department of Oral Molecular Regulation, Graduate School of Dentistry, Tohoku University, Sendai, Japan
,
Masanori Nakamura
3   Department of Anatomy, School of Dentistry, Showa University, Tokyo, Japan
,
Takashi Sasano
1   Department of Oral Diagnosis, Graduate School of Dentistry, Tohoku University, Sendai, Japan
,
Masao Ono
4   Department of Pathology, Graduate School of Medicine, Tohoku University, Sendai, Japan
,
Shunji Sugawara
2   Department of Oral Molecular Regulation, Graduate School of Dentistry, Tohoku University, Sendai, Japan
,
Yasuo Endo
2   Department of Oral Molecular Regulation, Graduate School of Dentistry, Tohoku University, Sendai, Japan
› Author Affiliations
Further Information

Publication History

Received: 24 June 2008

Accepted after major revision: 07 September 2009

Publication Date:
28 November 2017 (online)

Summary

In experimental animals, the lung rapidly removes intravenously injected 5-hydroxytryptamine (5HT), but the mechanism underlying this pulmonary 5HT removal (P-5HT-R) and the responsible cells remains unclear. 5HT reportedly induces rapid pulmonary platelet accumulation (P-PLT-A). Here, we examined the relationship between P-5HT-R and P-PLT-A in mice by comparing the platelet count in the blood with the endogenous 5HT in the tissues (a marker for platelets because the 5HT is largely contained within platelets). 5HT levels in murine blood and tissues were also examined after intravenous injection of 5HT. The data revealed that: (i) 5HT injection (at ≥ 0.04 μmol/kg) induced a transient P-PLT-A (occurring within 6 seconds), (ii) platelets rapidly took up injected 5HT, (iii) the P-5HT-R was saturated following injection of 5HT at 1 μmol/kg, (iv) ketanserin (5HT2-receptor antagonist) strongly inhibited P-PLT-A, (v) under fluoxetine (5HT-uptake inhibitor), 5HT levels at 6 seconds after 5HT injection were markedly higher in blood, but significantly lower in lung (versus fluoxetine-untreated mice), (vi) P-5HT-R was barely detectable in mutant mice with platelets lacking dense bodies, and was much reduced in platelet-depleted mice, (vii) 5HT injected intravenously at 10 μmol/kg had a half-life in the lung of < 20 seconds, and (viii) unlike 5HT, injected histamine was largely excreted by the kidney. These results demonstrate that platelets rapidly translocate into the lung upon stimulation of 5HT2 receptors, take up 5HT (and possibly swiftly metabolise it), and then return to the circulation. Hence, pulmonary platelet accumulation plays an important role in pulmonary 5HT removal in mice.

 
  • References

  • 1 Starling EH, Verney ED. The secretion of urine as studied on the isolated kidney. Proc R Soc London Ser B 1925; 97: 321-323.
  • 2 Rapport MM, Green AA, Page IH. Serum vasoconstrictor (serotonin). IV. Isolation and characterization. J Biol Chem 1948; 176: 1243-1251.
  • 3 Gaddum JH, Hebb CO, Silver A. et al. 5-Hydroxytryptamine. Pharmacological action and destruction in perfused lungs. Quart J Exp Physiol 1953; 38: 255-262.
  • 4 Davis RB, Wang Y. Rapid pulmonary removal of 5-hydroxytryptamine in the intact dog. Proc Soc Exp Biol 1965; 118: 799-800.
  • 5 Thomas DP, Vane JR. 5-Hydroxytryptamine in the circulation of the dog. Nature 1967; 216: 335-338.
  • 6 Alabaster VA, Bakhle YS. Removal of 5-hydroxytryptamine in the pulmonary circulation of rat isolated lungs. Br J Pharmacol 1970; 40: 468-482.
  • 7 Strum JM, Junod AF. Radioautographic demonstration of 5-hydroxytryptamine-3H uptake by pulmonary endothelial cells. J Cell Biol 1972; 54: 456-467.
  • 8 Kjellström T, Ahlman H, Dahlström A. et al. The cellular uptake of 5-hydroxytryptamine in the rat lung in vivo: a histochemical study. Acta Physiol Scand 1982; 116: 455-460.
  • 9 Anderson GM, Stevenson JM, Cohen DJ. Steadystate model for plasma free and platelet serotonin in man. Life Sci 1987; 41: 1777-1785.
  • 10 Klinger MHF. Platelets and inflammation. Anat Embryol 1997; 196: 1-11.
  • 11 Männel DN, Grau GE. Role of platelet adhesion in homeostasis and immunopathology. J Clin Pathol: Mol Pathol 1997; 50: 175-185.
  • 12 Weyrich AS, Zimmerman GA. Platelets: signaling cells in the immune continuum. Trends Immunol 2004; 05: 489-495.
  • 13 Feldman JM, Davis JA. Radioenzymatic assay of platelet serotonin, dopamine and norepinephrine in subjects with normal and increased serotonin production. Clin Chim Acta 1981; 109: 275-283.
  • 14 Oyekan AO, Botting JH. A minimally invasive technique for study of intravascular platelet aggregation in anesthetized rats. J Pharmacol Method 1986; 15: 271-277.
  • 15 Page CP, Paul W, Morley J. An in vivo model for studying platelet aggregation and disaggregation. Thromb Haemost 1982; 47: 210-213.
  • 16 Paul W, Gresele P, Momi S. et al. The effect of defibrotide on thromboembolism in the pulmonary vasculature of mice and rabbits and in cerebral vasculature of rabbits. Br J Pharmacol 1993; 110: 1565-1571.
  • 17 Mannaioni PF, Di Bello MG, Masini E. Platelets and inflammation: role of platelet-derived growth factor, adhesion molecules and histamine. Inflamm Res 1997; 46: 4-18.
  • 18 Yoshida M, Saiga K, Hato T. et al. Cappuccino mutation in an autoimmune-prone strain of mice suggested a role of platelet function in the progression of immune-complex crescentic glomerulonephritis. Arthritis Rheum 2006; 54: 2934-2943.
  • 19 Nagata Y, Shozaki Y, Nagahisa H. et al. Serum thrombopoietin level is not regulated by transcription but by the total counts of both megakaryocytes and platelets during thrombocytopenia and thrombocytosis. Thromb Haemost 1997; 77: 808-814.
  • 20 Yamaguchi K, Zhiqian Yu, Kumamoto H. et al. Involvement of Kupffer cells in lipopolysaccharide-induced rapid accumulation of platelets in the liver and the ensuing anaphylaxis-like shock in mice. Biochim Biophys Acta 2006; 1762: 269-275.
  • 21 Ohtaki Y, Shimauchi H, Yokochi T. et al. In vivo platelet response to lipopolysaccharide in mice: proposed method for evaluating new antiplatelet drugs. Thromb Res 2002; 108: 303-309.
  • 22 Zhao K, Ohtaki Y, Yamaguchi K. et al. LPS-induced platelet response and rapid shock in mice: contribution of O-antigen region of LPS and involvement of the lectin pathway of the complement system. Blood 2002; 100: 3233-3239.
  • 23 Yoshida A, Ohba M, Wu X. et al. Accumulation of platelets in the lung and liver and their degranulation following antigen-challenge in sensitized mice. Br J Pharmacol 2002; 137: 146-152.
  • 24 Endo Y, Nakamura M. The effect of lipopolysaccharide, interleukin-1 and tumor necrosis factor on the hepatic accumulation of 5-hydroxytryptamine and platelets in the mouse. Br J Pharmacol 1992; 105: 613-619.
  • 25 Yu Z, Ohtaki Y, Kai K. et al. Critical roles of platelets in lipopolysaccharide-induced lethality: effects of glycyrrhizin and possible strategy for acute respiratory distress syndrome. Int Immunopharmacol 2005; 05: 571-580.
  • 26 Endo Y. A simple method for determination of polyamines and histamine and its application to the assay of ornithine and histidine decarboxylase activities. Methods Enzymol 1983; 94: 42-47.
  • 27 Shibazaki M, Nakamura M, Endo Y. Biphasic, organ-specific, and strain-specific accumulation of platelets induced in mice by a lipopolysaccharide from Escherichia coli and its possible involvement in shock. Infect Immun 1996; 64: 5290-5294.
  • 28 Mattson DL. Comparison of arterial blood pressure in different strains of mice. Am J Hypertension 2001; 14: 405-408.
  • 29 Wish L, Furh J, Storey RH. Direct determinations of plasma, cell, and organ-blood volumes in normal and hypervolemic mice. Proc Soc Exp Biol Med 1950; 74: 644-648.
  • 30 De Clerck F. The role of serotonin in thrombogenesis. Clin Physiol Biochem 1990; 08: 40-49.
  • 31 Leysen JE, Wynants J, Eens A. et al. Ketanserin reduces a particular monoamine pool in peripheral tissues. Mol Pharmacol 1989; 35: 375-380.
  • 32 Leysen JE, Gommeren W, Janssen PA. Identification of non-serotonergic [3H] ketanserin binding sites on human platelets and their role in serotonin release. Eur J Pharmacol 1991; 206: 39-45.
  • 33 Ortiz J, Artigas F. Effects of monoamine uptake inhibitors on extracellular and platelet 5-hydroxytryptamine in rat blood: different effects of clomipramine and fluoxetine. Br J Pharmacol 1992; 105: 941-946.
  • 34 Honda S, Nemoto K, Mae T. et al. Mice with early onset of death (EOD) due to lupus glomerulonephritis. Clin Exp Immunol 1999; 116: 153-163.
  • 35 Ciciotte SL, Gwynn B, Moriyama K, et l. Cappuccino, a mouse model of Hermansky-Pudlak syndrome, encodes a novel protein that is part of the pallidinmuted complex (BLOC-1). Blood 2003; 101: 4402-4407.
  • 36 Falcon-Perez JM, Starcevic M, Gautam R. et al. BLOC-1, a novel complex containing the pallidin and muted proteins involved in the biogenesis of melanosomes and platelet dense granules. J Biol Chem 2002; 277: 28191-28199.
  • 37 Cerrito F, Lazzaro MP, Gaudio E. et al. 5HT2-receptors and serotonin release: their role in human platelet aggregation. Life Sci 1993; 53: 209-215.
  • 38 Stratz C, Trenk D, Bhatia HS. et al. Identification of 5HT3 receptors on human platelets: increased surface immunoreactivity after activation with adenosine diphosphate (ADP) and thrombin receptor-activating peptide (TRAP). Thromb Haemost 2008; 99: 784-786.
  • 39 Kaufman RM, Airo R, Pollack S. et al. Circulating megakaryocytes and platelet release in the lung. Blood 1965; 26: 720-731.
  • 40 Zucker-Franklin D, Phillip CS. Platelet production in the pulmonary capillary bed: new ultrastructural evidence for an old concept. Am J Pathol 2000; 157: 69-74.
  • 41 Sanders-Bush E, Mayer SE. 5-Hydroxytryptamine (serotonin): receptor agonists and antagonists. In: Goodman & Gilman’s The Pharmacological Basis of Therapeutics. 10th ed. McGraw-Hill; New York: 2001: 269-290.
  • 42 Vane JR. The release and fate of vasoactive hormones in the circulation. Br J Pharmacol 1969; 35: 209-242.
  • 43 Junod AF. Metabolism, production, and release of hormones and mediators in the lung. Am Rev Resp Dis 1975; 112: 93-108.
  • 44 Bakhle YS, Vane JR. Pharmacokinetic function of the pulmonary circulation. Physiol Rev 1974; 54: 1007-1045.
  • 45 Said SI. Metabolic functions of the pulmonary circulation. Circulation Res 1982; 50: 325-333.
  • 46 Gillis CN, Pitt BR. The fate of circulating amines within pulmonary circulation. Ann Rev Physiol 1982; 44: 269-281.
  • 47 Herd CM, Page CP. Pulmonary immune cells in health and disease: platelets. Eur Respir J 1994; 07: 1145-1160.
  • 48 Meseguer J, Esteban MÁ, Rodríguez A. Are thrombocytes and platelets true phagocytes?. Microscopy Res Technique 2002; 57: 491-497.
  • 49 Shibazaki M, Kawabata Y, Yokochi T. et al. Complement-dependent accumulation and degradation of platelets in the lung and liver induced following injection of lipopolysaccharides. Infect Immun 1999; 67: 5186-5191.
  • 50 Ohba M, Shibazaki M, Sasano T. et al. Platelet responses and anaphylaxis-like shock induced in mice by intravenous injection of whole cells of oral streptococci. Oral Microbiol Immunol 2004; 19: 26-30.